Gabrail Cancer Center Research

The trials here

What the 40 trials at this site are about, from their registry records.

Conditions

• Lung cancer13 trials
• Diffuse large B-cell lymphoma4 trials
• Follicular lymphoma4 trials
• Multiple myeloma4 trials
• Myelodysplastic syndromes4 trials
• Prostate cancer4 trials
• Acute myeloid leukaemia3 trials
• Colorectal cancer3 trials
• Mantle cell lymphoma3 trials
• Melanoma3 trials
• Myeloproliferative neoplasms3 trials
• Triple-negative breast cancer3 trials
• and 14 more

Phase

• Phase 1/213 trials
• Phase 311 trials
• Phase 15 trials
• Phase 25 trials
• Phase 2/33 trials

Status

• Recruiting11 trials
• Active, not recruiting10 trials
• Terminated9 trials
• Completed4 trials
• Withdrawn4 trials
• Enrolling by invitation1 trial
• Not yet recruiting1 trial

Lead sponsor

• Celgene2 trials
• Genprex, Inc.2 trials
• Krystal Biotech, Inc.2 trials
• Nuvation Bio Inc.2 trials
• Pfizer2 trials
• and 28 more

Running trials

• Not yet recruiting

  Study Using a Drug-device Combination Product to Determine Safety, Tolerability and Antitumor Activity for Patients With Advanced, Non-small Cell Lung Cancer

  NCT07864584· Phase 1/2· Nob Hill Therapeutics, Inc.· Source

  Contact: Carrie Smith, RN

• Recruiting

  A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

  NCT07723248· Phase 3· ORIC Pharmaceuticals· Source

• Recruiting

  INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)

  NCT07429266· Phase 3· Ono Pharmaceutical Co., Ltd.· Source

  Contact: Carrie Smith

• Recruiting

  A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States

  NCT07554521· Phase 2· BeOne Medicines· Source

  Contact: Study Director

• Recruiting

  This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  NCT06758401· Phase 3· Pfizer· Source

• Recruiting

  A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

  NCT06499285· Phase 3· Takeda· Source

  Contact: Nashat Gabrail (principal investigator)

• Recruiting

  Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

  NCT06712316· Phase 2/3· BioNTech SE· Source

• Active, not recruiting

  A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

  NCT06311721· Phase 3· Amgen· Source

• Recruiting

  Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

  NCT05703971· Phase 1/2· Genprex, Inc.· Source

  Contact: Carrie Smith

• Recruiting

  A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

  NCT06228326· Phase 1/2· Krystal Biotech, Inc.· Source

  Contact: Carrie Smith, RN

• Recruiting

  A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

  NCT05970497· Phase 1/2· Krystal Biotech, Inc.· Source

  Contact: Carrie Smith, RN

• Active, not recruiting

  A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

  NCT05800015· Phase 2/3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

  NCT05785767· Phase 2/3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma

  NCT05322590· Phase 1/2· Bexion Pharmaceuticals, Inc.· Source

• Active, not recruiting

  A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

  NCT05668988· Phase 3· Dizal Pharmaceuticals· Source

• Recruiting

  Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

  NCT04486833· Phase 1/2· Genprex, Inc.· Source

  Contact: Carrie Smith

• Active, not recruiting

  Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma

  NCT04674683· Phase 3· HUYABIO International, LLC.· Source

• Active, not recruiting

  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

  NCT04691804· Phase 3· Jiangsu HengRui Medicine Co., Ltd.· Source

• Recruiting

  The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

  NCT04329728· Phase 1/2· AVM Biotechnology Inc· Source

  Contact: Nashat Gabrail, MD

• Active, not recruiting

  A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

  NCT04224493· Phase 3· Epizyme, Inc.· Source

• Active, not recruiting

  A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer

  NCT04036682· Phase 1/2· Cullinan Therapeutics Inc.· Source

• Enrolling by invitation

  A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

  NCT04093570· Phase 2· Taiho Oncology, Inc.· Source

• Recruiting

  Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

  NCT01954992· Phase 3· Eleison Pharmaceuticals LLC.· Source

  Contact: Carrie Smith

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer5 recruiting
• Myelodysplastic syndromes2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Acute myeloid leukaemia1 recruiting
• Childhood cancers1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Follicular lymphoma1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Mantle cell lymphoma1 recruiting
• Melanoma1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Pancreatic cancer1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Terminated

  A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

  NCT06568692· Phase 2· Processa Pharmaceuticals· Source

• Terminated

  Study of ALE.C04 in Patients With Head and Neck Cancer

  NCT06054477· Phase 1/2· Alentis Therapeutics AG· Source

• Recruiting

  A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

  NCT06022029· Phase 1· OncoNano Medicine, Inc.· Source

• Recruiting

  Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

  NCT05727176· Phase 2· Taiho Oncology, Inc.· Source

  Contact: Taiho Oncology, INC

• Terminated

  A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

  NCT05556616· Phase 1· Teva Branded Pharmaceutical Products R&D LLC· Source

• Recruiting

  A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

  NCT05253651· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

• Withdrawn

  Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC

  NCT05191004· Phase 1/2· Nuvation Bio Inc.· Source

• Withdrawn

  Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC

  NCT05191017· Phase 1/2· Nuvation Bio Inc.· Source

• Recruiting

  Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

  NCT05320198· Phase 1/2· Disc Medicine, Inc· Source

  Contact: Disc Medicine Clinical Trials

• Terminated

  PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

  NCT05107856· Phase 1· Prelude Therapeutics Incorporated· Source

• Completed

  To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)

  NCT04894591· Jazz Pharmaceuticals· Source

• Recruiting

  DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

  NCT04920617· Phase 2· ImmunoVaccine Technologies, Inc. (IMV Inc.)· Source

• Completed

  Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

  NCT04742959· Phase 1/2· TransThera Sciences (Nanjing), Inc.· Source

• Completed

  Prevention of Colorectal Cancer Through Multiomics Blood Testing

  NCT04369053· Freenome Holdings Inc.· Source

• Terminated

  A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

  NCT03530683· Phase 1· Pfizer· Source

• Terminated

  Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma

  NCT02400242· Phase 1· Celgene· Source

• Terminated

  Connect® MM- The Multiple Myeloma Disease Registry

  NCT01081028· Celgene· Source